clinical trial · NCT06374459
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Hormone Receptor Positive HER-2 Negative Metastatic Breast CancerZumsemetinibCapecitabineZoledronic acidDenosumab
brief summary
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
started
Jan 30, 2025
primary completion
May 31, 2032
completion
May 31, 2032
last updated
Apr 20, 2026
official title
A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol